scholarly article | Q13442814 |
P356 | DOI | 10.1126/SCIENCE.1371891 |
P8608 | Fatcat ID | release_el7fpb5gnfhu7lip4g5i54zgru |
P698 | PubMed publication ID | 1371891 |
P50 | author | Robert Gallo | Q469904 |
P2093 | author name string | S. Nakamura | |
R. C. Gallo | |||
Y. Osada | |||
M. Sekiguchi | |||
N. Sakamoto | |||
N. G. Tanaka | |||
S. Sakurada | |||
S. Z. Salahuddin | |||
P433 | issue | 5050 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | cell wall | Q128700 |
peptidoglycan | Q206920 | ||
P304 | page(s) | 1437-1440 | |
P577 | publication date | 1992-03-01 | |
1992-03-13 | |||
P1433 | published in | Science | Q192864 |
P1476 | title | Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex | |
P478 | volume | 255 |
Q24678972 | AIDS-associated Kaposi's sarcoma (KS) cells express oncostatin M (OM)-specific receptor but not leukemia inhibitory factor/OM receptor or interleukin-6 receptor. Complete block of OM-induced KS cell growth and OM binding by anti-gp130 antibodies |
Q40925893 | AIDS-related Kaposi's sarcoma. A template for the translation of molecular pathogenesis into targeted therapeutic approaches |
Q33948194 | Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor |
Q40915770 | Advances in Kaposi's sarcoma |
Q41508935 | An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action |
Q72076470 | Analysis of experimental antiangiogenic therapy |
Q72680667 | Antitumor effects of GBS toxin: a polysaccharide exotoxin from group B beta-hemolytic streptococcus |
Q35366050 | Antiviral therapy for human immunodeficiency virus infections |
Q36363956 | Apolipoprotein E (ApoE), a novel heparin-binding protein inhibits the development of Kaposi's sarcoma-like lesions in BALB/c nu/nu mice |
Q34155667 | Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS. |
Q73147184 | Combining suramin and a chimeric toxin directed to basic fibroblast growth factor receptors increases therapeutic efficacy against human melanoma in an animal model |
Q48506360 | Contradictory Concepts in the Etiology and Regression of Kaposi's Sarcoma. The Ferenc Györkey Memorial Lecture |
Q44270368 | Do more than discuss that unusual case. Write it up! |
Q41498045 | Effects of group B Streptococcus toxin on long-term survival of mice bearing transplanted Madison lung tumors |
Q35489176 | Endogenous synthesis of peptidoglycan in eukaryotic cells; a novel concept involving its essential role in cell division, tumor formation and the biological clock |
Q41648545 | Inhibition of malignant angiogenesis |
Q55472387 | Inhibition of tumor-induced angiogenesis by a synthetic lipid A analogue with low endotoxicity, DT-5461. |
Q71804597 | Inhibitory effect of Korean mistletoe (Viscum album coloratum) extract on tumour angiogenesis and metastasis of haematogenous and non-haematogenous tumour cells in mice |
Q46661407 | Involvement of vascular endothelial growth factor in Kaposi's sarcoma associated with acquired immunodeficiency syndrome |
Q40987325 | Kaposi's sarcoma: advances and perspectives |
Q35752847 | Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis |
Q27729397 | Structural studies of the binding of the anti-ulcer drug sucrose octasulfate to acidic fibroblast growth factor |
Q72093201 | Treatment of Kaposi's sarcoma |
Q40395719 | Treatment of Kaposi's sarcoma. Current guidelines and future perspectives |
Q35215799 | Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth |
Q73164417 | [Anti-angiogenesis: a new approach to tumor therapy?] |
Search more.